Pyridine and pyrimidine amides as CAMK2 inhibitors

Novel pyridine and pyrimidine amides are developed to target and inhibit CAMK2 kinases, addressing the lack of effective treatments for CAMK2-related disorders, offering therapeutic benefits for conditions like heart failure and asthma.

WO2026112047A1PCT designated stage Publication Date: 2026-05-28BRISTOL MYERS SQUIBB CO
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/US2025/055905
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-11-19
Filing Date
2025-11-18
Publication Date
2026-05-28

AI Technical Summary

Technical Problem

Current treatments for diseases associated with Calcium calmodulin dependent protein kinase 2 (CAMK2) kinases, such as heart failure, fibrosis, and cardiac arrhythmias, lack effective inhibitors that can specifically target and regulate CAMK2D, CAMK2A, and CAMK2B.

Method used

Development of novel pyridine and pyrimidine amides that act as selective inhibitors of CAMK2 kinases, particularly CAMK2D, CAMK2A, and CAMK2B, which can be used in pharmaceutical compositions to treat various disorders.

Benefits of technology

The compounds effectively inhibit CAMK2 kinases, providing therapeutic benefits for conditions like heart failure, fibrosis, and cardiac arrhythmias, while also being applicable for other disorders such as diabetes, asthma, and anxiety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2025055905_28052026_PF_FP_ABST
    Figure US2025055905_28052026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention provides compounds of Formula (I): wherein all of the variables are as defined herein. These compounds are inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2), which may be used as medicaments for the treatment of heart failure, and related diseases.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Methods and compositions for treating pulmonary hypertension and related diseases and disorders

    WO2009009561A1

  • Pfkfb3 inhibitors and their uses

    WO2020080979A1

  • Fused heteroaryl compounds and their use as camkii inhibitors

    WO2022067082A1